Clinical trials: IDIOPATHIC PARKINSON'S DISEASE
Parkinson's Disease
Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist (12 Month Extension)
To determine the long-term safety and efficacy of a dose range of safinamide of 50-200 mg/day, p.o., compared to placebo, as add-on therapy in patients with early idiopathic Parkinson's disease who are currently receiving a…
- Trial name
- NCT00642889
- Testing
- Safinamide
- Volunteers
- 227 people
- Sponsor
- Newron Pharmaceuticals SPA
Parkinson Disease
Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease
This is a multicenter longitudinal study in about 300 patients with Idiopathic Parkinson's disease, who will be evaluated in several clinical centers with a clinical assessment and an oculometric examination during a time period…
- Trial name
- PALOMA (NCT05862649)
- Testing
- NeuraLight
- Where
- 5 sites in United States, Portugal and 3 more
- Volunteers
- 300 people
- Sponsor
- NeuraLight
Idiopathic Parkinson Disease
Effect of Safinamide on Parkinson's Disease Related Chronic Pain
Primary objective: To evaluate the potential efficacy of safinamide 100 mg once daily (OD), compared with placebo, as add-on therapy for PD-related chronic pain Secondary objectives: Percentage of pain responders Clinical Global…
- Trial name
- NCT03841604
- Testing
- Safinamide Methanesulfonate
- Where
- 45 sites in Austria, France and 3 more
- Volunteers
- 94 people
- Sponsor
- Zambon SpA
Parkinson Disease
ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson's Disease
Evaluate the safety and efficacy of unilateral focused ultrasound pallidotomy using the ExAblate 4000 System in the management of dyskinesia symptoms or motor fluctuations for medication refractory, advanced idiopathic…
- Trial name
- NCT03319485
- Testing
- ExAblate Pallidotomy
- Where
- 20 sites in United States, Canada and 6 more
- Volunteers
- 92 people
- Sponsor
- InSightec
Idiopathic Parkinson's Disease
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
Parkinson's Disease is a major neurodegenerative disorder in which there is a progressive loss of dopamine-containing neurons. The understanding that PD is a syndrome of dopamine (DA) deficiency led to the introduction in the…
- Trial name
- SETTLE (NCT00627640)
- Testing
- Safinimide 50-100 mg/day
- Where
- 121 sites in United States, Australia and 19 more
- Volunteers
- 549 people
- Sponsor
- Newron Pharmaceuticals SPA
Idiopathic Parkinson's Disease
Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy
This trial is being conducted to assess the effects of Rotigotine over Placebo on improvement of Apathy and motor symptoms in subjects with early-stage and advanced stage idiopathic Parkinson´s Disease.
- Trial name
- BRIGHT (NCT01782222)
- Testing
- Rotigotine
- Where
- 42 sites in United States, Austria and 5 more
- Volunteers
- 122 people
- Sponsor
- UCB BIOSCIENCES GmbH
Levodopa-induced Dyskinesia
Safety, Tolerability, PK and PD Study of Neu-120 in the Treatment of Levodopa-induced Dyskinesia
The purpose of this study is to determine the safety, tolerability, pharmacokinetic and pharmacodynamic effects of single doses of Neu-120 in Parkinson's disease patients with levodopa-induced dyskinesia.
- Trial name
- NCT00607451
- Testing
- Neu-120
- Where
- Israel
- Volunteers
- 8 people
- Sponsor
- Neurim Pharmaceuticals Ltd.
All Diagnosed Health Conditions, ADD/ADHD
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research.
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis
- Trial name
- NCT01931644
- Where
- United States
- Volunteers
- 17,667 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Parkinson's Disease
Safety of CERE-120 (AAV2-NTN) in Subjects With Idiopathic Parkinson's Disease
This is a Phase I dose escalating open-label study designed to assess the safety, tolerability and biologic activity of an in vivo AAV2 mediated delivery of the gene encoding NTN (CERE-120).
- Trial name
- NCT00252850
- Testing
- CERE-120: AAV2-NTN
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Sangamo Therapeutics
Idiopathic Parkinson's Disease
Randomized Safety Study of CVT-301 Compared to an Observational Control Group
This study is a 12-month, open-label, randomized, multicenter study which will evaluate the safety and efficacy of CVT-301 for the treatment of up to 5 OFF episodes per day in Parkinson's Disease (PD) patients experiencing motor…
- Trial name
- NCT02352363
- Testing
- CVT-301, Observational cohort
- Where
- 76 sites in United States, Austria and 12 more
- Volunteers
- 408 people
- Sponsor
- Acorda Therapeutics
Idiopathic Parkinson's Disease
A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
This is a study to assess the efficacy and safety of oral Istradefylline (KW-6002) in patients with moderate to severe Parkinson's Disease.
- Trial name
- KW-6002 (NCT01968031)
- Testing
- Istradefylline 40 mg, Istradefylline 20 mg
- Where
- 89 sites in United States, Canada and 6 more
- Volunteers
- 613 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Idiopathic Parkinson Disease
Transdermal Rotigotine User Surveillance Study
This study will be conducted in an observational multiple-cohort design aimed at acquiring clinical, treatment, health status, and economic data. Patients with Parkinson's disease (PD) will be enrolled.
- Trial name
- TRUST (NCT00599339)
- Where
- 211 sites in Czechia, Denmark and 8 more
- Volunteers
- 2,195 people
- Sponsor
- UCB Pharma
Parkinson Disease, Idiopathic
Clinical Study of HER-096 in Healthy Volunteer Subjects and Patients With Parkinson's Disease
In this clinical study, the safety and tolerability of HER-096 and the way the body interacts with the drug (pharmacokinetics) will be investigated. The clinical study consists of two parts.
- Trial name
- NCT06659562
- Testing
- HER-096
- Where
- Finland
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Herantis Pharma Plc.
Parkinson's Disease With Cognitive Impairments
A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease
The purpose of this research trial is to determine if safinamide (experimental drug) can improve cognition in cognitively impaired but non-demented Parkinson's disease patients.
- Trial name
- NCT01211587
- Testing
- safinamide
- Where
- 15 sites in United States, Spain
- Volunteers
- 103 people
- Sponsor
- Newron Pharmaceuticals SPA
Parkinson Disease
To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications
This is a randomized, double-blind, placebo-controlled, multicenter study in participants with Parkinson's disease (PD) with motor fluctuations.
- Trial name
- NCT06553027
- Testing
- CVN424 75 mg, CVN424 150 mg
- Where
- 94 sites in United States, Australia and 7 more
- Volunteers
- 330 people
- Sponsor
- Cerevance
Parkinson's Disease
Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease
The objective of this open-label extension is to assess the long-term effect of the 24-hour transdermal delivery of rotigotine on motor function, sleep quality, and nocturnal and non-motor symptoms of Parkinson's disease.
- Trial name
- NCT00519532
- Testing
- Rotigotine
- Where
- 21 sites in United States, Australia and 9 more
- Volunteers
- 84 people
- Sponsor
- UCB Pharma
Parkinson Disease
Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease
The purpose of this study is to establish safety for CEP-1347 and to determine an efficacious dose in the treatment of Parkinson's disease.
- Trial name
- NCT00040404
- Testing
- CEP-1347 10mg, CEP1347 25mg, CEP-1347 50mg
- Where
- 66 sites in United States, Canada and 1 more
- Volunteers
- 806 people
- Sponsor
- Cephalon
Idiopathic Parkinson's Disease, Parkinson's Disease
Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease
Safety and efficacy of AADC gene transfer in participants with Parkinson's disease.
- Conditions
- Idiopathic Parkinson's Disease, Parkinson's Disease, Basal Ganglia Disease, Brain Diseases
- Trial name
- NCT03065192
- Testing
- VY-AADC01
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Neurocrine Biosciences
Parkinson Disease
Post Marketing Surveillance Study in Patients With Idiopathic Parkinson's Disease
Documentation of the effect of an direct or overlapping switch from another dopamine agonist to Sifrol® on motor function, psychopathological disturbances and mood, assessment of the reasons for the switch and the reasons for…
- Trial name
- NCT02231255
- Testing
- Sifrol®
- Volunteers
- 1,216 people
- Sponsor
- Boehringer Ingelheim
IDIOPATHIC PARKINSON'S DISEASE
Rotigotine Versus Placebo As Double Blind Study To Evaluate The Efficacy In Early Stage Idiopathic Parkinson's Disease Patients
The primary objective is to demonstrate that the Rotigotine transdermal patch is efficacious in Chinese subjects with early-stage idiopathic Parkinson's disease.
- Trial name
- NCT01646268
- Testing
- Rotigotine
- Where
- 24 sites in China
- Volunteers
- 249 people
- Sponsor
- UCB Pharma